Böhler T - Search Results

1

Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer.

Pchejetski D, Böhler T, Stebbing J, Waxman J. Pchejetski D, et al. Among authors: bohler t. Nat Rev Urol. 2011 Sep 13;8(10):569-678. doi: 10.1038/nrurol.2011.117. Nat Rev Urol. 2011. PMID: 21912422 Review.

2

FTY720 (fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1.

Pchejetski D, Bohler T, Brizuela L, Sauer L, Doumerc N, Golzio M, Salunkhe V, Teissié J, Malavaud B, Waxman J, Cuvillier O. Pchejetski D, et al. Among authors: bohler t. Cancer Res. 2010 Nov 1;70(21):8651-61. doi: 10.1158/0008-5472.CAN-10-1388. Epub 2010 Oct 19. Cancer Res. 2010. PMID: 20959468 Free article.

3

Therapeutic potential of targeting SK1 in human cancers.

Alshaker H, Sauer L, Monteil D, Ottaviani S, Srivats S, Böhler T, Pchejetski D. Alshaker H, et al. Among authors: bohler t. Adv Cancer Res. 2013;117:143-200. doi: 10.1016/B978-0-12-394274-6.00006-6. Adv Cancer Res. 2013. PMID: 23290780 Review.

4

Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1.

Alshaker H, Wang Q, Kawano Y, Arafat T, Böhler T, Winkler M, Cooper C, Pchejetski D. Alshaker H, et al. Among authors: bohler t. Oncotarget. 2016 Dec 6;7(49):80943-80956. doi: 10.18632/oncotarget.13115. Oncotarget. 2016. PMID: 27821815 Free PMC article.

5

Combination of RAD001 (everolimus) and docetaxel reduces prostate and breast cancer cell VEGF production and tumour vascularisation independently of sphingosine-kinase-1.

Alshaker H, Wang Q, Böhler T, Mills R, Winkler M, Arafat T, Kawano Y, Pchejetski D. Alshaker H, et al. Among authors: bohler t. Sci Rep. 2017 Jun 14;7(1):3493. doi: 10.1038/s41598-017-03728-3. Sci Rep. 2017. PMID: 28615679 Free PMC article.

6

Core shell lipid-polymer hybrid nanoparticles with combined docetaxel and molecular targeted therapy for the treatment of metastatic prostate cancer.

Wang Q, Alshaker H, Böhler T, Srivats S, Chao Y, Cooper C, Pchejetski D. Wang Q, et al. Among authors: bohler t. Sci Rep. 2017 Jul 19;7(1):5901. doi: 10.1038/s41598-017-06142-x. Sci Rep. 2017. PMID: 28724986 Free PMC article.

7

FTY720 Inhibits Tumor Necrosis Factor-alpha-Induced Proliferation and Extracellular Signal-Regulated Kinase Phosphorylation of Human Smooth Muscle Cells.

Böhler T, Kamar N, Etienne L, Galvani S, Canivet C, Thomsen M, Salvayre R, Nègre-Salvayre A, Rostaing L, Auge N. Böhler T, et al. Transplant Proc. 2009 Mar;41(2):705-6. doi: 10.1016/j.transproceed.2008.12.017. Transplant Proc. 2009. PMID: 19328962

8

Effect of FTY720 on apoptosis of smooth muscle cells.

Böhler T, Guillebaud J, Etienne L, Canivet C, Kamar N, Rostaing L, Thiers JC, Galvani S, Augé N, Salvayre R, Nègre-Salvayre A, Thomsen M. Böhler T, et al. Transplant Proc. 2007 Oct;39(8):2624-6. doi: 10.1016/j.transproceed.2007.08.012. Transplant Proc. 2007. PMID: 17954194

9

FTY720 (fingolimod) in renal transplantation.

Budde K, Schütz M, Glander P, Peters H, Waiser J, Liefeldt L, Neumayer HH, Böhler T. Budde K, et al. Among authors: bohler t. Clin Transplant. 2006;20 Suppl 17:17-24. doi: 10.1111/j.1399-0012.2006.00596.x. Clin Transplant. 2006. PMID: 17100697 Review.

10

Current perspectives on FTY720.

Martini S, Peters H, Böhler T, Budde K. Martini S, et al. Among authors: bohler t. Expert Opin Investig Drugs. 2007 Apr;16(4):505-18. doi: 10.1517/13543784.16.4.505. Expert Opin Investig Drugs. 2007. PMID: 17371198 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

122 results

Search Page